News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CSPC Pharmaceutical Group (01093.HK) HB1901 Clinical Study Meets Primary Efficacy Endpoint
CSPC Pharmaceutical Group (01093.HK) announced that the Ib/III clinical study of its self-developed sirolimus for injection (albumin-bound) (HB1901) for the treatment of advanced m...
Reset
Send
The window will close in 5 seconds
CSPC Pharmaceutical Group (01093.HK) HB1901 Clinical Study Meets Primary Efficacy Endpoint
Close
Recommend
13
Positive
24
Negative
15
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

CSPC Pharmaceutical Group (01093.HK)  +0.350 (+4.768%)    Short selling $185.59M; Ratio 24.126%   announced that the Ib/III clinical study of its self-developed sirolimus for injection (albumin-bound) (HB1901) for the treatment of advanced malignant perivascular epithelioid cell tumor (PEComa) has successfully met its pre-specified primary efficacy endpoint, demonstrating statistically significant differences and clear clinical benefits.

The company stated that HB1901 has shown outstanding efficacy and is expected to fill the domestic treatment gap for this indication, potentially becoming the first standard-of-care therapy in China for advanced malignant PEComa.

Related News UBS Upgrades CSPC PHARMA (01093.HK) to Buy, Says Valuation Yet to Reflect AI Drug R&D Strength
In February last year, HB1901 was granted Breakthrough Therapy Designation by the National Medical Products Administration. Currently, multiple clinical trials exploring the efficacy and safety of sirolimus for injection (albumin-bound) in combination with different drugs across various tumor types are progressing steadily. (ss/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.